ScoreWhy is Glaxosmithkline Pharmaceuticals Ltd ?
1
Poor long term growth as Net Sales has grown by an annual rate of 3.62% and Operating profit at 15.07% over the last 5 years
2
Flat results in Mar 26
3
Stock is technically in a Mildly Bearish range
- The technical trend has deteriorated from Mildly Bearish on 22-May-26
- A key technical factor - Bollinger Band has been Bearish since 22 May 2026
4
With ROE of 45, it has a Very Expensive valuation with a 17.3 Price to Book Value
- The stock is trading at a premium compared to its peers' average historical valuations
- Over the past year, while the stock has generated a return of -23.74%, its profits have risen by 10.5% ; the PEG ratio of the company is 3.7
5
Underperformed the market in the last 1 year
- Even though the market (BSE500) has generated returns of 0.10% in the last 1 year, the stock has hugely underperformed and has generate negative returns of -23.74% returns
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Glaxosmi. Pharma should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Glaxosmi. Pharma for you?
Medium Risk, Low Return
Absolute
Risk Adjusted
Volatility
Glaxosmi. Pharma
-8.11%
-0.83
28.66%
Sensex
-11.8%
-0.49
12.94%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
3.44%
EBIT Growth (5y)
14.36%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
Net Debt is too low
Net Debt to Equity (avg)
-1.21
Sales to Capital Employed (avg)
1.97
Tax Ratio
26.31%
Dividend Payout Ratio
93.21%
Pledged Shares
0
Institutional Holding
12.59%
ROCE (avg)
-239.91%
ROE (avg)
45.70%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
41
Industry P/E
36
Price to Book Value
18.98
EV to EBIT
31.30
EV to EBITDA
29.76
EV to Capital Employed
-83.69
EV to Sales
10.18
PEG Ratio
3.65
Dividend Yield
2.24%
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
45.02%
Loading Valuation Snapshot...
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Bullish
Mildly Bearish
Dow Theory
No Trend
Mildly Bullish
OBV
Bullish
No Trend
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend1What is working for the Company
NO KEY POSITIVE TRIGGERS
-3What is not working for the Company
PBT LESS OI(Q)
At Rs 278.69 cr has Fallen at -10.1% (vs previous 4Q average
PAT(Q)
At Rs 237.18 cr has Fallen at -7.1% (vs previous 4Q average
Loading Valuation Snapshot...
Here's what is not working for Glaxosmi. Pharma
Profit Before Tax less Other Income (PBT) - Quarterly
At Rs 278.69 cr has Fallen at -10.1% (vs previous 4Q average)
over average PBT of the previous four quarters of Rs 310.01 CrMOJO Watch
Near term PBT trend is very negative
PBT less Other Income (Rs Cr)
Profit After Tax (PAT) - Quarterly
At Rs 237.18 cr has Fallen at -7.1% (vs previous 4Q average)
over average PAT of the previous four quarters of Rs 255.19 CrMOJO Watch
Near term PAT trend is negative
PAT (Rs Cr)
Non Operating Income - Quarterly
Highest at Rs 43.76 cr
in the last five quartersMOJO Watch
Increased income from non business activities may not be sustainable
Non Operating Income
